CSL Behring (http://www.cslbehring.com/homepage) is a global leader in the plasma protein biotherapeutics industry. They research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. 

Their products are produced at facilities in Bern, Switzerland; Marburg, Germany; Kankakee, Illinois and Broadmeadows, Australia, in accordance with international safety and quality standards. The company also operates CSL Plasma, one of the world’s largest plasma collection networks throughout the United States and Germany. CSL Behring employs more than 9,000 people in 19 countries. 

According to the news on China Food and Drug Administration website, CFDA recently issued a notice on import drug electronic supervision requirement. However, due to the cultural difference among different countries, import drug enterprises may have inadequate understanding about China drug electronic supervision implementation policy standards.

In order to better meet China drug electronic supervision demands, CSL cooperates with an important supporting enterprise of China electronic supervision website—Beijing Acctrue Technology Co., Ltd. Acctrue provides CSL with China policies consultation, technical document consultation of network access test, production line technology implementation and utilization consultation services.

In face of China policies change, import drug enterprises have a hard time to adapt quickly. As one of important supporting enterprises for China drug electronic supervision website, Beijing Acctrue Technology Co., Ltd has provided over 3,000 pharmaceutical enterprises with electronic supervision Serialization and consulting solutions. Although CSL factories disperse in German, Switzerland and America, Acctrue has successfully implemented services for it and CSL has become one of Acctrue’s typical consultancy service customers.